Literature DB >> 17442573

Shedding light on Merlin's wizardry.

Tomoyo Okada1, Liru You, Filippo G Giancotti.   

Abstract

Inactivation of the tumor suppressor Merlin, encoded by the NF2 (Neurofibromatosis type 2) gene, contributes to malignant conversion in many cell types. Merlin is an Ezrin-Radixin-Moesin protein and localizes underneath the plasma membrane at cell-cell junctions and other actin-rich sites. Recent studies indicate that Merlin mediates contact inhibition of proliferation by blocking recruitment of Rac to the plasma membrane. In mitogen-stimulated cells, p21-activated kinase phosphorylates Ser518 in the C-terminus of Merlin, inactivating the growth suppressive function of the protein. Furthermore, the myosin phosphatase MYPT1-PP1delta, has been identified as a direct activator of Merlin and its inhibition has been linked to malignant transformation. Finally, studies in the fruit fly Drosophila melanogaster have revealed that Merlin functions together with the band 4.1 protein Expanded to promote [corrected] the endocytosis of many signaling receptors, limiting [corrected] their accumulation at the plasma membrane, and to activate [corrected] the Hippo signaling pathway. Here, we review these recent findings and their relevance to the tumor suppressor function of Merlin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17442573     DOI: 10.1016/j.tcb.2007.03.006

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN: 0962-8924            Impact factor:   20.808


  47 in total

Review 1.  Epithelial cell polarity, stem cells and cancer.

Authors:  Fernando Martin-Belmonte; Mirna Perez-Moreno
Journal:  Nat Rev Cancer       Date:  2011-12-15       Impact factor: 60.716

2.  Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.

Authors:  Jaishri O Blakeley; D Gareth Evans; John Adler; Derald Brackmann; Ruihong Chen; Rosalie E Ferner; C Oliver Hanemann; Gordon Harris; Susan M Huson; Abraham Jacob; Michel Kalamarides; Matthias A Karajannis; Bruce R Korf; Victor-Felix Mautner; Andrea I McClatchey; Harry Miao; Scott R Plotkin; William Slattery; Anat O Stemmer-Rachamimov; D Bradley Welling; Patrick Y Wen; Brigitte Widemann; Kim Hunter-Schaedle; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2011-12-02       Impact factor: 2.802

3.  Angiomotin-like proteins associate with and negatively regulate YAP1.

Authors:  Wenqi Wang; Jun Huang; Junjie Chen
Journal:  J Biol Chem       Date:  2010-12-27       Impact factor: 5.157

4.  Schwannomin/merlin promotes Schwann cell elongation and influences myelin segment length.

Authors:  Courtney Thaxton; Marga Bott; Barbara Walker; Nicklaus A Sparrow; Stephen Lambert; Cristina Fernandez-Valle
Journal:  Mol Cell Neurosci       Date:  2010-12-21       Impact factor: 4.314

Review 5.  Successful design and conduct of genome-wide association studies.

Authors:  Christopher I Amos
Journal:  Hum Mol Genet       Date:  2007-06-27       Impact factor: 6.150

6.  Yes-associated protein 1 is activated and functions as an oncogene in meningiomas.

Authors:  Gilson S Baia; Otavia L Caballero; Brent A Orr; Anita Lal; Janelle S Y Ho; Cynthia Cowdrey; Tarik Tihan; Christian Mawrin; Gregory J Riggins
Journal:  Mol Cancer Res       Date:  2012-05-22       Impact factor: 5.852

7.  Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.

Authors:  Kristy Truong; Iram Ahmad; J Jason Clark; Alison Seline; Tyler Bertroche; Brian Mostaert; Douglas J Van Daele; Marlan R Hansen
Journal:  Neuroscience       Date:  2018-02-03       Impact factor: 3.590

8.  Drosophila PI4KIIIalpha is required in follicle cells for oocyte polarization and Hippo signaling.

Authors:  Yan Yan; Natalie Denef; Charm Tang; Trudi Schüpbach
Journal:  Development       Date:  2011-03-23       Impact factor: 6.868

Review 9.  Deregulation of cell signaling in cancer.

Authors:  Filippo G Giancotti
Journal:  FEBS Lett       Date:  2014-02-20       Impact factor: 4.124

10.  Loss of NF2/Merlin expression in advanced sporadic colorectal cancer.

Authors:  Tamara Cačev; Gorana Aralica; Božo Lončar; Sanja Kapitanović
Journal:  Cell Oncol (Dordr)       Date:  2013-12-10       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.